Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas

Tarek Wehbe, Michael Glantz, Hak Choy, Lisa Glantz, Selina Cortez, Wallace Akerley, Pam Mills, Bernard Cole

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The new anticancer agent Taxol appears to potentiate the effects of radiation on brain tumor cell lines in vitro and was recently evaluated by our group as a radiosensitizer in a phase I study for primary brain tumors. In that study, we administered Taxol as a three-hour IV infusion repeated every week for six weeks and gave daily cranial irradiation concurrently for a total of 6000 rads. We reviewed the charts of the 60 patients who participated in the study, and identified twelve patients who underwent a second surgery after treatment because of progressive symptoms and an enlarging intracranial mass on MRI. Pathologically, each patient showed prominent radionecrosis, and other evidence of accelerated radiation changes (confluent areas of coagulative necrosis, bizarre nuclei, marked thickening and fibrinoid changes in multiple blood vessels). These changes were noted many weeks earlier than would be expected after radiation therapy alone and were independent of age, and tumor histology. We postulate that the accelerated radiation changes may be due to the radiation sensitizing effects of Taxol. We also noted a change of the pattern of tumor recurrence, compared to historic reports, and a dose-necrosis relationship where the resected tumor is formed completely of necrotic tissue in patients who received 150 mg/m2 or higher dose of Taxol. These observations may be of significance for future study design.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalJournal of neuro-oncology
Issue number3
StatePublished - 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas'. Together they form a unique fingerprint.

Cite this